Korro Bio Inc

NASDAQ:KRROUnited States

Korro Bio, Inc. is a biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Its Oligonucleotide Promoted Editing of RNA (OPERA) is a foundational platform for RNA editing, which is designed to edit RNA in vivo by delivering an oligonucleotide guide that can target specific RNA sequences. OPERA co-opts the cell’s natural process with its synthetic oligo and catalyzes a single base change to modify protein sequence and function without the need to permanently modify one’s genome. The Company's focus areas include the liver and central nervous system (CNS).

Contact Information

Headquarters

One Kendall Square. Building 600-700 Suite 6-401CAMBRIDGE, MA, United States 02139

Phone

617-468-1999

Fax

302-636-5454

Executives

Chairman of the Board, Co-Founder

Nessan Bermingham

President, Chief Executive Officer, Director

Ram Aiyar

Chief Financial Officer, Principal Accounting Officer, Treasurer, Principal Financial Officer

Vineet Agarwal

Chief Operating Officer

Todd Chappell

Senior Vice President, General Counsel, Corporate Secretary

Shelby Walker